Systemic Sclerosis Clinical Trials

128 recruitingLast updated: June 18, 2026

There are 128 actively recruiting systemic sclerosis clinical trials across 47 countries. Studies span Phase 1, Phase 2, Not Applicable, Early Phase 1, Phase 3, Phase 4. Top locations include Ann Arbor, Michigan, United States, Paris, France, Chicago, Illinois, United States. Updated daily from ClinicalTrials.gov.


Systemic Sclerosis Trials at a Glance

128 actively recruiting trials for systemic sclerosis are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Phase 1 with 38 trials, with the heaviest enrollment activity in Ann Arbor, Paris, and Chicago. Lead sponsors running systemic sclerosis studies include Hacettepe University, Beijing GoBroad Hospital, and China Immunotech (Beijing) Biotechnology Co., Ltd..

Browse systemic sclerosis trials by phase

Treatments under study

About Systemic Sclerosis Clinical Trials

Looking for clinical trials for Systemic Sclerosis? There are currently 65 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Systemic Sclerosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Systemic Sclerosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 128 trials

Recruiting
Phase 2

Safety and Tolerability of TOP-N53 Applied on Digital Ulcers in Patients With Systemic Sclerosis

Digital Ulcers in Systemic Sclerosis
Topadur Pharma AG15 enrolled6 locationsNCT06954597
Recruiting
Phase 1

A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease

SLE (Systemic Lupus)Diffuse Cutaneous Systemic SclerosisSystemic Sclerosis+4 more
CRISPR Therapeutics80 enrolled14 locationsNCT06925542
Recruiting
Phase 3

Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis

Interstitial Lung Disease With Systemic Sclerosis
University Hospital, Tours102 enrolled1 locationNCT06549231
Recruiting
Phase 1

US Zamto-cel Autoimmune Diseases

Systemic Lupus ErythematosusDiffuse Cutaneous Systemic SclerosisSystemic Sclerosis (SSc)+1 more
Miltenyi Biomedicine GmbH48 enrolled1 locationNCT06708845
Recruiting
Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PRO-203 in Healthy Volunteers and Participants With Systemic Sclerosis

Healthy VolunteersSclerodermaSystemic Sclerosis (SSc)+1 more
Prolium Bioscience, Inc74 enrolled2 locationsNCT07641634
Recruiting
Not Applicable

Efficacy of a Personalized Rehabilitation Program of Facial Involvement in Systemic Sclerosis

RehabilitationSystemic SclerosisFace+1 more
University Hospital, Strasbourg, France60 enrolled1 locationNCT05177380
Recruiting
Phase 2

A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis

Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals200 enrolled128 locationsNCT06470048
Recruiting
Phase 2

EncompaSSc: Evaluation of MTX-474 in Participants With Diffuse Cutaneous Systemic Sclerosis (dcSSc)

Diffuse Cutaneous Systemic Sclerosis
Mediar Therapeutics85 enrolled6 locationsNCT07287670
Recruiting

EACVI Study on Multimodality Cardiovascular Imaging of Inflammatory Cardiovascular Diseases

PericarditisRheumatoid ArthritisSarcoidosis+10 more
Assistance Publique - Hôpitaux de Paris5,000 enrolled1 locationNCT07077304
Recruiting
Phase 1

A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

Rheumatoid ArthritisSystemic Lupus ErythematosusSystemic Sclerosis+1 more
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company270 enrolled54 locationsNCT05869955
Recruiting
Phase 1Phase 2

A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis+1 more
Nkarta, Inc.240 enrolled17 locationsNCT06733935
Recruiting
Phase 1

A Study of AZD0120 in Autoimmune Diseases

Rheumatoid ArthritisIdiopathic Inflammatory MyopathiesSystemic Sclerosis
AstraZeneca27 enrolled18 locationsNCT07295847
Recruiting
Phase 2

AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.

SclerodermaRheumatoid Arthritis (RA)Sjogren Syndrome+6 more
Artiva Biotherapeutics, Inc.90 enrolled52 locationsNCT06991114
Recruiting
Phase 1

A Phase 1 Open-label Study to Evaluate Safety in Healthy Participants and Participants With Autoimmune Diseases

HealthyIdiopathic Inflammatory MyopathiesSystemic Sclerosis+1 more
Xencor, Inc.60 enrolled1 locationNCT07284797
Recruiting
Phase 1

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

Systemic Lupus Erythematosus (SLE)Systemic Sclerosis (SSc)Lupus Nephritis+2 more
Fate Therapeutics244 enrolled21 locationsNCT06308978
Recruiting
Phase 1Phase 2

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

SclerodermaSystemic Sclerosis
Cabaletta Bio12 enrolled10 locationsNCT06328777
Recruiting
Phase 3

A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

Systemic Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company92 enrolled55 locationsNCT07335562
Recruiting
Early Phase 1

CD19/BCMA UCAR-T for B Cell-Related Autoimmune Disease

IgA Nephropathy (IgAN)Autoimmune DiseasesSystemic Sclerosis (SSc)+3 more
The Children's Hospital of Zhejiang University School of Medicine15 enrolled1 locationNCT07586267
Recruiting
Phase 1Phase 2

Controlling Hyperactive Immunity With Long-lived Lymphocytes

Rheumatoid Arthritis (RA)Autoimmune Rheumatologic DiseaseDiffuse Cutaneous Systemic Sclerosis+1 more
Quell Therapeutics Limited16 enrolled6 locationsNCT07473154
Recruiting
Phase 2

Intralesional Injection of STS in Treatment of Calcinosis

DermatomyositisSystemic Sclerosis (SSc)Mixed Connective Tissue Disease (MCTD)+1 more
Robyn T. Domsic, MD, MPH20 enrolled1 locationNCT06672822